Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.
The Sheffield Trophoblastic Disease Centre treats about 25 patients with persistent trophoblastic disease each year. A total of 75% of patients are classified as low risk according to the Charing Cross Hospital prognostic scoring system and receive methotrexate (MTX) 50 mg, i.m., on days 1, 3, 5, 7...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group
1997
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228140/ |